India Pharma Outlook Team | Thursday, 18 June 2026
Specialty drugs are becoming the next big growth driver for Indian pharmaceutical companies as the industry looks beyond traditional generic medicines.
For decades, Indian drugmakers built their global presence through affordable generics, especially in the US market.
However, rising competition, pricing pressure, and lower margins are pushing companies to focus on specialty drugs, biosimilars, and complex therapies that offer better profitability and long-term growth.
Leading companies such as Sun Pharma, Dr. Reddy’s Laboratories, Cipla, and Lupin are increasing investments in specialty medicines and differentiated products as they prepare for the next phase of growth. The shift reflects a broader transformation in the Indian pharma industry, where innovation and high-value products are becoming more important than volume-driven generic sales.
The US generics market, which has been a key revenue source for Indian pharmaceutical companies, has become increasingly challenging. Intense competition among manufacturers has led to continuous price erosion, making it harder for companies to maintain profit margins.
To reduce dependence on generic medicines, pharma firms are focusing on:
Industry experts believe these segments can provide sustainable growth while helping companies diversify their revenue streams.
Also Read: Indian CDMO 2.0 Guide: Risk-Sharing and Hybrid Models
Among Indian drugmakers, Sun Pharma has emerged as a key player in the specialty segment. The company's Global Innovative Medicines business generated more than USD 1.4 billion in FY26 and contributed over 22 percent of its total sales. Specialty products have also supported growth across markets such as Brazil, China, and Romania.
Dr. Reddy’s Laboratories is strengthening its portfolio of differentiated products and biosimilars. The company sees specialty medicines as a major growth opportunity and continues to invest in complex product development to expand its global presence.
Cipla is leveraging its strong respiratory business and branded prescription portfolio to drive growth. The company also considers biosimilars a significant opportunity due to their growing demand and relatively low market penetration.
Lupin is expanding its operations in India, Brazil, and other international markets. The company currently has more than 60 respiratory and injectable products under development and is targeting the launch of its first biosimilars in the US market during FY27.
Biosimilars are emerging as one of the most promising areas for Indian pharmaceutical companies. These medicines offer alternatives to expensive biologic drugs and are expected to witness strong demand globally.
The industry's growing focus on specialty medicines and biosimilars marks a significant shift from its traditional business model. Companies are investing in research, product differentiation, and advanced therapies to create long-term value.
The transition toward specialty drugs signals a new chapter for India's pharmaceutical industry. As competition intensifies in the generics market, companies that successfully build strong specialty and biosimilar businesses are likely to emerge as future industry leaders.
.jpg)
